Replimune Group, Inc. (REPL) DCF Valuation

Replimune Group, Inc. (REPL) Valoración de DCF

US | Healthcare | Biotechnology | NASDAQ
Replimune Group, Inc. (REPL) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Replimune Group, Inc. (REPL) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¿Busca determinar el valor intrínseco de Replimune Group, Inc.? Nuestra calculadora DCF (REPL) integra datos del mundo real con extensas características de personalización, lo que le permite refinar sus pronósticos y mejorar sus estrategias de inversión.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -52.6 -76.5 -114.4 -170.3 -230.2 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 1.8 4.1 4.6 2.4 2.7 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -54.4 -80.6 -119.0 -172.8 -232.9 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 168.6 476.3 395.7 583.4 420.7 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 3.0 3.0 3.1 2.9 4.9
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 3.4 2.4 3.7 5.4 2.6 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure -6.5 -2.4 -2.3 -2.3 -5.7 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % -0.18943 -0.18943 -0.18943 -0.18943 -0.18943 -0.18943 -0.18943 -0.18943 -0.18943 -0.18943
EBITAT -54.4 -80.6 -119.0 -173.0 -233.3 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -58.7 -79.9 -115.5 -171.1 -241.1 2.3 .0 .0 .0 .0
WACC, % 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6 9.6
PV UFCF
SUM PV UFCF 2.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 2
Net Debt 1
Equity Value 1
Diluted Shares Outstanding, MM 67
Equity Value Per Share 0.01

What You Will Get

  • Genuine Replimune Data: Preloaded financial metrics – from revenue to EBIT – based on actual and projected figures for Replimune Group, Inc. (REPL).
  • Complete Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates to suit your analysis.
  • Immediate Valuation Updates: Automatic recalculations to evaluate the effects of changes on Replimune’s fair value.
  • Flexible Excel Template: Designed for quick edits, scenario testing, and comprehensive projections.
  • Efficient and Precise: Eliminate the need to build models from scratch while ensuring accuracy and adaptability.

Key Features

  • 🔍 Real-Life REPL Financials: Pre-filled historical and projected data for Replimune Group, Inc. (REPL).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Replimune’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Replimune’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • Step 1: Download the prebuilt Excel template with Replimune Group, Inc.'s (REPL) data included.
  • Step 2: Explore the pre-filled sheets and understand the key metrics related to Replimune.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Replimune's intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose This Calculator for Replimune Group, Inc. (REPL)?

  • Designed for Experts: A sophisticated tool utilized by industry analysts, CFOs, and consultants.
  • Accurate Data: Replimune's historical and projected financials preloaded for precision.
  • Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly: Step-by-step guidance to navigate the calculation process.

Who Should Use This Product?

  • Investors: Evaluate Replimune Group's valuation before making stock transactions.
  • CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
  • Startup Founders: Understand the valuation strategies of successful biotech companies like Replimune.
  • Consultants: Provide comprehensive valuation analyses for client projects.
  • Students and Educators: Utilize current market data to learn and teach valuation principles.

What the Template Contains

  • Pre-Filled Data: Contains Replimune Group, Inc.'s historical financials and projections.
  • Discounted Cash Flow Model: An editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for WACC calculation based on user-defined inputs.
  • Key Financial Ratios: Evaluate Replimune's profitability, efficiency, and capital structure.
  • Customizable Inputs: Easily modify revenue growth, profit margins, and tax rates.
  • Clear Dashboard: Visuals and tables summarizing essential valuation outcomes.

No products were found matching.